Many drugs, including glatiramer acetate, reduce relapse in MS patients by altering the differentiation of immature T cells toward Th2 production and increasing IL-4 levels and inhibiting IFNγ secretion. This evidence concerns the gene IL4 and myeloid sarcoma.